GPX4 and cancer: Silencing P65 or EAAT3 increases ROS levels and reduces GSH synthesis, but these changes alone are insufficient to trigger significant cell death due to the robust ferroptosis-resistance mechanisms in cancer cells, including the xCT-GSH-GPX4 system and other protective pathways.